Through a reversible deal, MaSTherCell has been acquired by Orgenesis (a leader in the emerging fields of cellular therapy and re-generative medicine for the treatment of Type 1 Diabetes) in March 2015. MaSTherCell will be responsible for the development and the commercialization of Orgenesis’ product and will also maintain his CDMO core business activity in an independent way.
Press release: https://www.orgenesis.com/news-media/press-releases/detail/37/orgenesis-acquires-cell-therapy-manufacturer-masthercell